These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 37258402)
1. Corrigendum to "Berberine regulates PADI4-related macrophage function to prevent lung cancer" [Int. Immunopharmacol. 110 (2022) 108965]. Gu W; Zhang M; Gao F; Niu Y; Sun L; Xia H; Li W; Zhang Y; Guo Z; Du G Int Immunopharmacol; 2023 Jul; 120():110366. PubMed ID: 37258402 [No Abstract] [Full Text] [Related]
2. Berberine regulates PADI4-related macrophage function to prevent lung cancer. Gu W; Zhang M; Gao F; Niu Y; Sun L; Xia H; Li W; Zhang Y; Guo Z; Du G Int Immunopharmacol; 2022 Sep; 110():108965. PubMed ID: 35764017 [TBL] [Abstract][Full Text] [Related]
3. Corrigendum to 'In-vitro and in-vivo anti-breast cancer activity of synergistic effect of berberine and exercise through promoting the apoptosis and immunomodulatory effects' [Int. Immunopharmacol. 87 (2020) 106787]. Ma W; Zhang Y; Yu M; Wang B; Xu S; Zhang J; Li X; Ye X Int Immunopharmacol; 2020 Nov; 88():106899. PubMed ID: 32827917 [No Abstract] [Full Text] [Related]
4. Corrigendum to "In vivo anti-apoptosis activity of novel berberine-loaded chitosan nanoparticles effectively ameliorates osteoarthritis" [Int. Immunopharmacol. 28(1) (2015) 34-43]. Zhou Y; Liu SQ; Peng H; Yu L; He B; Zhao Q Int Immunopharmacol; 2022 Jul; 108():108844. PubMed ID: 35562271 [No Abstract] [Full Text] [Related]
5. Corrigendum to "In vivo anti-apoptosis activity of novel berberine-loaded chitosan nanoparticles effectively ameliorates osteoarthritis" [Int. Immunopharmacol. 28(1) (2015) 34-43]. Zhou Y; Liu SQ; Peng H; Yu L; He B; Zhao Q Int Immunopharmacol; 2020 Sep; 86():106796. PubMed ID: 32674050 [No Abstract] [Full Text] [Related]
6. Corrigendum to "Anti-arthritis effect of berberine associated with regulating energy metabolism of macrophages through AMPK/HIF-1α pathway". [Int. Immunopharmacol. 87 (2020) 106830]. Yu Y; Cai W; Zhou J; Lu H; Wang Y; Song Y; He R; Pei F; Wang X; Zhang R; Liu H; Wei F Int Immunopharmacol; 2021 Oct; 99():107911. PubMed ID: 34353734 [No Abstract] [Full Text] [Related]
7. Corrigendum to "Berberine derivative DCZ0358 induced oxidative damage by ROS-mediated JNK signaling in DLBCL cells" [Int. Immunopharmacol. 125(Part A) (2023) 111139]. Feng Q; Hu K; Hu H; Lu Y; Zhang H; Wang G; Zhang Q; Xu Z; Gao X; Jia X; Zhu H; Song D; Yi H; Peng Y; Wu X; Li B; Zhu W; Shi J Int Immunopharmacol; 2024 Aug; 137():112499. PubMed ID: 38909009 [No Abstract] [Full Text] [Related]
8. Corrigendum to "Secretory Nogo-B regulates Th2 differentiation in the lung cancer microenvironment" [Int. Immunopharmacol. 140 (2024) 112763]. Qin C; Li W; Zhang Y; Wang Z; Leng Y; Ma J; Qin C; Cheng S; Xue L; Song K; Huang B Int Immunopharmacol; 2024 Dec; 142(Pt A):113108. PubMed ID: 39289042 [No Abstract] [Full Text] [Related]
9. Corrigendum to "GTS-21 attenuates ACE/ACE2 ratio and glycocalyx shedding in lipopolysaccharide-induced acute lung injury by targeting macrophage polarization derived ADAM-17" [Int. Immunopharmacol. 129 (2024) 111603]. Zhu W; Wang F; Hu C; Zhao Q; Zhang D; Wang X; Hu B; Li J Int Immunopharmacol; 2024 May; 132():111914. PubMed ID: 38582738 [No Abstract] [Full Text] [Related]
10. Retraction notice to "Corrigendum to "MLL1 promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis by activating the TRIF/NF-κB signaling pathway via H3K4me3 enrichment in the TLR4 promoter region"" [Int. Immunopharmacol. 82 (2020) 106220] [Int. Immunopharmacol. 92 (2021) 107321]. Zhang Y; Ji T; Ma S; Wu W Int Immunopharmacol; 2023 Apr; 117():109865. PubMed ID: 36822094 [No Abstract] [Full Text] [Related]
11. Corrigendum to "Hydrogen gas inhalation enhances alveolar macrophage phagocytosis in an ovalbumin-induced asthma model" [Int. Immunopharmacol. 74 (2019) 105646]. Huang P; Wei S; Huang W; Wu P; Chen S; Tao A; Wang H; Liang Z; Chen R; Yan J; Zhang Q Int Immunopharmacol; 2022 Nov; 112():109124. PubMed ID: 36070977 [No Abstract] [Full Text] [Related]
12. Corrigendum to "Evaluation of the immunomodulatory and anti-inflammatory activity of Bakuchiol using RAW 264.7 macrophage cell lines and in animal models stimulated by lipopolysaccharide (LPS)" [Int. Immunopharmacol. 91 (2021) 107264]. Kumar A; Sawhney G; Kumar Nagar R; Chauhan N; Gupta N; Kaul A; Ahmed Z; Sangwan PL; Satheesh Kumar P; Yadav G Int Immunopharmacol; 2022 Oct; 111():109003. PubMed ID: 35778365 [No Abstract] [Full Text] [Related]
13. Corrigendum to "Rapamycin regulates osteogenic differentiation through Parkin-mediated mitophagy in rheumatoid arthritis" [Int. Immunopharmacol. 113(Part B) (2022) 109407]. Chen Q; Fan K; Song G; Wang X; Zhang J; Chen H; Qin X; Lu Y; Qi W Int Immunopharmacol; 2023 Nov; 124(Pt A):110941. PubMed ID: 37718175 [No Abstract] [Full Text] [Related]
14. Corrigendum to "Oridonin regulates the polarized state of Kupffer cells to alleviate nonalcoholic fatty liver disease through ROS-NF-κB" [Int. Immunopharmacol. 101(Part B) (2021) 108290]. Zhu Y; Ruan S; Shen H; Guan Q; Zhai L; Yang Y Int Immunopharmacol; 2023 Jun; 119():110302. PubMed ID: 37193623 [No Abstract] [Full Text] [Related]
15. Corrigendum to "Plasma levels of 12 different cytokines correlate to PD-1 inhibitor combined chemotherapy responses in advanced non-small-cell lung cancer patient" [Int. Immunopharmacol. 124(Part A) (2023) 110888]. Peng Y; Qi Q; Zhu M; Zhang Y; Bao Y; Liu Y Int Immunopharmacol; 2023 Nov; 124(Pt A):110976. PubMed ID: 37778965 [No Abstract] [Full Text] [Related]
16. Corrigendum to "Emodin attenuates acute lung injury in cecal-ligation and puncture rats" [Int. Immunopharmacol. 85 (2020) 106626]. Guo R; Li Y; Han M; Liu J; Sun Y Int Immunopharmacol; 2023 Sep; 122():110700. PubMed ID: 37507324 [No Abstract] [Full Text] [Related]
17. Corrigendum to "Inhibition of MRP4 alleviates sepsis-induced acute lung injury in rats" [Int. Immunopharmacol. 72 (2019) 211-217]. Xia W; Zhang H; Pan Z; Li G; Zhou Q; Hu D; Liu Y Int Immunopharmacol; 2023 Sep; 122():110699. PubMed ID: 37500384 [No Abstract] [Full Text] [Related]
18. Corrigendum to "MEGF6 prevents sepsis-induced acute lung injury in mice" [Int. Immunopharmacol. 123 (2023) 110727]. Liang H; Liu G; Zeng W; Fan Q; Nie Z; Hu H; Zhang R; Xie S Int Immunopharmacol; 2024 May; 133():111787. PubMed ID: 38641473 [No Abstract] [Full Text] [Related]
19. Corrigendum to "Sophoricoside attenuates lipopolysaccharide-induced acute lung injury by activating the AMPK/Nrf2 signaling axis" [Int. Immunopharmacol. 90 (2021) 107187]. Wu YX; Zeng S; Wan BB; Wang YY; Sun HX; Liu G; Gao ZQ; Chen D; Chen YQ; Lu MD; Pang QF Int Immunopharmacol; 2023 Nov; 124(Pt A):111008. PubMed ID: 37806791 [No Abstract] [Full Text] [Related]
20. Corrigendum to "Taxifolin ameliorates Benzo[a]pyrene-induced lung injury possibly via stimulating the Nrf2 signalling pathway" [Int. Immunopharmacol. 96 (2021) 107566]. Islam J; Shree A; Vafa A; Afzal SM; Sultana S Int Immunopharmacol; 2023 Jun; 119():110096. PubMed ID: 37095029 [No Abstract] [Full Text] [Related] [Next] [New Search]